Caris Life Sciences
CAI· Services· Fiscal year ends in December
CEO pay in FY2025
David Dean Halbert is the CEO of Caris Life Sciences and was paid $20.4M in FY2025 (Dec), up 804%.
PayNo stock prices for these years
Executives3
See all- 1David Dean HalbertChief Executive OfficerFY2025
- 2David SpetzlerPresidentFY2025
- 3J. Russel DentonSenior Vice President, General Counsel and SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCaris Life Sciences paid its 3 named executives $37.3M in total in FY2025 (Dec). CEO David Dean Halbert was paid $20.4M of that.
| Name | ||
|---|---|---|
| David Dean HalbertChief Executive Officer | ||
| David SpetzlerPresident | ||
| J. Russel DentonSenior Vice President, General Counsel and Secretary | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Caris Life Sciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board8
See all- Laura I. JohansenDirector · 17 yr on the boardIndependentCompensation—Paid as an executive
- Danny PhillipsDirector · 10 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Brian J. BrilleDirector · 7 yr on the boardNot independent—Paid as an executive
- Joseph E. GilliamDirector · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
- David FredricksonDirector · 1 yr on the boardIndependent—Paid as an executive
- Jeffrey VacircaDirector · 1 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Shared directors
- BiogenLloyd B. Minor1 shared
Activity
Filings2
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
